ArticleClinical and experimental medicine2008
The value of antinuclear antibodies in primary biliary cirrhosis.
Article in Clinical and experimental medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- [Meta-analysis of anti-GP210 antibody and anti-SP100 antibody detection for diagnosis of primary biliary cirrhosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2016Pooled it
- Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis.PloS one · 2014Pooled it
- Autoantibodies in the diagnostics, prognostics and follow-up of primary biliary cholangitis.Journal of translational autoimmunity · 2026Review
- The Personalized Management of Primary Biliary Cholangitis in the Era of Precision Medicine: Current Challenges and Future Perspectives.Journal of personalized medicine · 2025Review
- [Research progress on early-stage primary biliary cholangitis accompanied by portal hypertension].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Review
- Risk Stratification in Primary Biliary Cholangitis.Journal of clinical medicine · 2023Review
- Role of autoantibodies in the clinical management of primary biliary cholangitis.World journal of gastroenterology · 2023Review
- Performance of indirect immunofluorescence test and immunoblot tests in the evaluation of antinuclear and antimitochondrial antibodies.Turkish journal of medical sciences · 2022Article
- Using two-step cluster analysis to classify inpatients with primary biliary cholangitis based on autoantibodies: A real-world retrospective study of 537 patients in China.Frontiers in immunology · 2022Article
- How to report the antinuclear antibodies (anti-cell antibodies) test on HEp-2 cells: guidelines from the ICAP initiative.Immunologic research · 2021Article
- Detection of Autoantibodies Against Nucleoporin p62 in Sera of Patients With Primary Biliary Cholangitis.Annals of laboratory medicine · 2019Article
- Primary biliary cholangitis triggered by DAAs-induced HCV clearance: a biological proof of concept.Therapeutic advances in chronic disease · 2018Article
- Autoimmune liver disease-related autoantibodies in patients with biliary atresia.World journal of gastroenterology · 2018Article
- Diagnostic value of anti-gp210 antibodies in primary biliary cirrhosis: a case-based review.BMJ case reports · 2013Article
- Humoral autoimmune response heterogeneity in the spectrum of primary biliary cirrhosis.Hepatology international · 2013Article
- Etiopathogenesis of primary biliary cirrhosis: an overview of recent developments.Hepatology international · 2013Article
- Risk factors for hepatic decompensation in patients with primary biliary cirrhosis.World journal of gastroenterology · 2013Article
- Is identification of anti-SSA and/or -SSB antibodies necessary in serum samples referred for antinuclear antibodies testing?Journal of clinical laboratory analysis · 2012Article
- Identification of new autoantigens for primary biliary cirrhosis using human proteome microarrays.Molecular & cellular proteomics : MCP · 2012Article
- Performance parameters of the conventional serological markers for autoimmune hepatitis.Digestive diseases and sciences · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAlthough autoantibodies have been used for the diagnosis of primary biliary cirrhosis (PBC), their role has not been clarified. In this study, we try to explore the value of gp210 antibody and anti-centromere antibodies (ACA) in PBC.
methodsAnti-gp210 and ACA were tested in 140 PBC patients by ELISA and indirect immunofluorescence respectively. Their association with clinical, pathological data and prognosis was analysed.
results30.5% of PBC patients had positive anti-gp210 antibody and 29.2% had ACA. The anti-gp210 antibody positive group had higher Mayo risk scores and lower serum albumin levels compared to the negative one. Patients with positive anti-gp210 antibody were more likely to develop hepatic failure (p<0.05, OR=9.8460, 95% CI: 1.067-90.901) than patients with negative anti-gp210 antibody. More patients with positive ACA developed portal hypertension than patients with negative ACA (p<0.05, OR=9.259; 95% CI: 1.027-88.410). Furthermore, concurrent Sjögren's syndrome (SjS) and PBC was significantly more likely in the ACA positive group than in the negative ones (68.4% in ACA positive group, 20.7% in ACA negative group p<0.001).
conclusionsBoth anti-gp210 antibody and ACA are related to severe disease course and poor prognosis. For PBC patients with positive ACA, further examinations should be made to detect underlying SjS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.